Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lesinurad/Allopurinol FDC vs Co-administration in Healthy Subjects
NCT03272425Phase 1Completed
- Sponsor
- Ardea Biosciences, Inc.
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lesinurad + allopurinol in gout (4 arms), sponsored by Ardea Biosciences, Inc. Primary endpoints: Maximum Observed Concentration at Day 22, Area Under the Curve to Last Quantifiable Timepoint at Day 22 and 3 more. Started Aug 2017; status: completed.
02
Drugs
lesinurad + allopurinol
03
Conditions
gout
Beyond the preview
Go deeper on NCT03272425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272425.